|
Market Closed -
Other stock markets
|
Pre-market 16:20:12 | |||
| 59.70 USD | +5.42% |
|
59.42 | -0.46% |
| 07-21 | Barclays Initiates Forte Biosciences at Overweight With $74 Price Target | MT |
| 07-09 | Forte Biosciences, Inc. - Special Call |
Company Valuation: Forte Biosciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 31.57 | 21 | 29.86 | 145.2 | 486.3 | 1,459 | - | - |
| Change | - | -33.49% | 42.17% | 386.3% | 234.91% | 200% | - | - |
| Enterprise Value (EV) | 31.57 | 21 | 29.86 | 145.2 | 486.3 | 1,459 | 1,459 | 1,459 |
| Change | - | -33.49% | 42.17% | 386.3% | 234.91% | 200% | 0% | 0% |
| P/E | -1.38x | -1.25x | - | -1.87x | -5.79x | -14.5x | -14x | -13.7x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | - | - | 0.1x | 1.1x | -3.94x | -4.8x |
| Capitalization / Revenue | - | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | - | - | - | -0x | -0x | -15x | -11.2x | -9.28x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -38.75 | -20 | - | -12.17 | -4.71 | -4.106 | -4.252 | -4.373 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | -36.6 | -70.66 | -97.38 | -130.5 | -157.2 |
| Net income 1 | -21.71 | -13.88 | - | -35.48 | -69.38 | -95.54 | -130.4 | -155.7 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 53.50 | 25.00 | 20.54 | 22.71 | 27.27 | 59.70 | 59.70 | 59.70 |
| Nbr of stocks (in thousands) | 590 | 840 | 1,453 | 6,393 | 17,831 | 24,436 | - | - |
| Announcement Date | 31/03/22 | 31/03/23 | 18/03/24 | 28/03/25 | 31/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -14.54x | - | - | - | 1.46B | |
| 21.08x | 6.49x | 14.2x | 1.51% | 55.92B | |
| 33.57x | 8.33x | 25.41x | 0.06% | 56.67B | |
| -18.45x | 4.44x | -7.77x | -.--% | 23.28B | |
| -42.05x | 13.36x | -39.35x | -.--% | 23.28B | |
| 25.7x | 5.07x | 13.38x | -.--% | 20.54B | |
| 24.87x | 4.83x | 15.68x | -.--% | 17.78B | |
| -617.89x | 37.85x | -1571.42x | -.--% | 15.9B | |
| 44.16x | 17.85x | 45.97x | 0.08% | 14.64B | |
| 17.51x | 5.07x | 11.83x | -.--% | 13.99B | |
| Average | -52.60x | 11.48x | -165.79x | 0.18% | 24.35B | |
| Weighted average by Cap. | -25.92x | 9.81x | -92.78x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- FBRX Stock
- Valuation Forte Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
